Changes in the Rate of Human Papilloma Virus Serotypes after Vaccine Implementation: A Descriptive Study  

作　　者：Ana María Colino Gallardo Montserrat de la Torre Serrano Lone Nielsen Alejandro Pascual Martín Concepción Millana de Ynes María Jesús González Fuensalida Patricia Barreiro Sanabria Eva Rodríguez Escudero Dolores García López Aranzazu Gómez Rodríguez Rosa Rodero Villanueva María Jesús Fernández Aceñero Ana María Colino Gallardo;Montserrat de la Torre Serrano;Lone Nielsen;Alejandro Pascual Martín;Concepción Millana de Ynes;María Jesús González Fuensalida;Patricia Barreiro Sanabria;Eva Rodríguez Escudero;Dolores García López;Aranzazu Gómez Rodríguez;Rosa Rodero Villanueva;María Jesús Fernández Aceñero(Department of Surgical Pathology, Hospital Clínico San Carlos, Madrid, Spain;Department of Surgical Pathology, Hospital Universitario del Sureste, Madrid, Spain;Grupo de Investigación en Anatomía Patológica, Hospital Clínico San Carlos, IdISSC, Madrid, Spain;Department of Legal Medicine, Psychiatry and Surgical Pathology, Complutense University of Madrid, Madrid, Spain)

机构地区：[1]Department of Surgical Pathology, Hospital Clínico San Carlos, Madrid, Spain [2]Department of Surgical Pathology, Hospital Universitario del Sureste, Madrid, Spain [3]Grupo de Investigación en Anatomía Patológica, Hospital Clínico San Carlos, IdISSC, Madrid, Spain [4]Department of Legal Medicine, Psychiatry and Surgical Pathology, Complutense University of Madrid, Madrid, Spain

出　　处：《Open Journal of Obstetrics and Gynecology》2023年第5期934-949,共16页妇产科期刊（英文）

摘　　要：Background: The main objective of this study is to describe the rate of the different serotypes of HPV in cervical cytologies and biopsies in three different periods: 2002-2006 (prior to the implementation of the vaccination programs in Spain), 2009-2011 (shortly after this implementation) and 2020 (almost 15 years after introduction of the vaccine) at a single hospital. Methods: This is an observational, descriptive, retrospective study based on the review of the results of the determination of the HPV serotype using the commercial kit (Genomica^®;PharmaMar LTD) in cervical liquid-based cytologies and biopsies at a single large tertiary hospital, Hospital Clínico San Carlos, in Madrid, Spain. We have collected the data from three different time periods: 2002-2006;2009-2011, and 2020 to try to understand the potential changes associated with the use of the vaccine. Results: In these time periods we have reviewed the data from 1420 women. In the three periods the most frequent serotype was HPV 16, followed by HPV 18 or a combination of both. The most frequent low risk serotype was HPV 6 followed by the combination of HPV 6 and 11. It has been verified in our study that the prevalence of the category “others”, constituted by the three risk groups, has undergone a progressive increase, beginning with an infection rate of 65.43% in 2002-2006 to finally rise up to 90.92% in the year 2020. Conclusions: Our study reveals an increase in the number of infections by the HPV serotypes that are not included in the tetravalent vaccine.Background: The main objective of this study is to describe the rate of the different serotypes of HPV in cervical cytologies and biopsies in three different periods: 2002-2006 (prior to the implementation of the vaccination programs in Spain), 2009-2011 (shortly after this implementation) and 2020 (almost 15 years after introduction of the vaccine) at a single hospital. Methods: This is an observational, descriptive, retrospective study based on the review of the results of the determination of the HPV serotype using the commercial kit (Genomica^®;PharmaMar LTD) in cervical liquid-based cytologies and biopsies at a single large tertiary hospital, Hospital Clínico San Carlos, in Madrid, Spain. We have collected the data from three different time periods: 2002-2006;2009-2011, and 2020 to try to understand the potential changes associated with the use of the vaccine. Results: In these time periods we have reviewed the data from 1420 women. In the three periods the most frequent serotype was HPV 16, followed by HPV 18 or a combination of both. The most frequent low risk serotype was HPV 6 followed by the combination of HPV 6 and 11. It has been verified in our study that the prevalence of the category “others”, constituted by the three risk groups, has undergone a progressive increase, beginning with an infection rate of 65.43% in 2002-2006 to finally rise up to 90.92% in the year 2020. Conclusions: Our study reveals an increase in the number of infections by the HPV serotypes that are not included in the tetravalent vaccine.

关 键 词：HPV SEROTYPES CERVIX VACCINE Women’s Health 

分 类 号：R73[医药卫生—肿瘤]